Protocol Ledger

Clinical Cooperative Network · Consolidated Sponsor Hub

SWOG Cancer Research Network: Clinical Trials & FDA Approval Profile

SWOG Cancer Research Network (Global / Institutional) sponsors 53 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 41 active protocols (28 recruiting now), 8 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)7.5%
Median Closed Enrollment vs National (145 pts)73 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for SWOG Cancer Research Network
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)53
Active Pipeline (Recruiting Now)41 (28)
Completed vs Stopped Early8 / 4 (7.5%)
Median Closed Actual Enrollment73 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With SWOG Cancer Research Network
Hospital Research SiteLocationShared Protocols
Cancer Care Specialists of Illinois - DecaturDecatur, IL34
Decatur Memorial HospitalDecatur, IL32
University of Oklahoma Health Sciences CenterOklahoma City, OK32

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by SWOG Cancer Research Network
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT05642611Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral NeuropathyPhase IIIRECRUITING
NCT03851445Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung CancerPhase II/IIIRECRUITING
NCT07393555Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An ExpandedPhase IIRECRUITING
NCT06116682Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)Phase IIRECRUITING
NCT06616584Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment WPhase II/IIIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the SWOG Cancer Research Network Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI